Results 61 to 70 of about 20,495 (161)

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. [PDF]

Front Endocrinol (Lausanne)
Jun JE, Oh DH, Jeong IK, Ryu HJ, Hwang YC, Ahn KJ, Chung HY, Kim KP.   +7 more
europepmc   +1 more source

Continuous glucose monitoring-based evaluation of percentage coefficient of variation (%CV) as a metric of intraday glycemic variability in South India. [PDF]

Sci Rep
Hussain MA, Kumar H A, Lingaiah M.
europepmc   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction. [PDF]

J Diabetes Investig
Ohkuma T, Aotani R, Sakamoto W, Oshiro A, Ago T.   +4 more
europepmc   +1 more source

Understanding Diabetes Distress: A Study of Contributing Factors Among Adults With Type 2 Diabetes in Rural East Godavari, Andhra Pradesh. [PDF]

Cureus
Meka RJ, Sundaram M S, Rani K S G, Mani V, Natrajan M.   +4 more
europepmc   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Evaluation of %CV and average glucose derived from pre- and postprandial 6-point glucose measurements for assessing hypoglycemia risk. [PDF]

J Diabetes Investig
Soga R, Torimoto K, Uemura F, Okada Y, Nakayamada S.   +4 more
europepmc   +1 more source

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. [PDF]

Drug Des Devel Ther
Aulifa DL, Wibisono TTDW, Ningsih JD, Christy GDAB, Pertiwi DS, Praja HM, Gazzali AM, Amaliah S, Budiman A.   +8 more
europepmc   +1 more source

Discovery of novel quinazoline-sulfonamide derivatives with promising antidiabetic activity. [PDF]

Front Chem
Zayed MF, Muhammad Y, Alqurain AA, Banafa MAA, Omar AM.   +4 more
europepmc   +1 more source